Beckman Coulter/NexGen
This article was originally published in The Gray Sheet
Executive Summary
Beckman Coulter agrees to buy the remaining 80% of NexGen Diagnostics, which was spun off from Lumigen when Beckman Coulter bought Lumigen in 2006 (1"The Gray Sheet" Oct. 9, 2006, In Brief). NexGen's assets are intellectual property unrelated to current products. The technology will "simplify and automate certain types of immunodiagnostics and nucleic acid testing in remarkable ways, dramatically enhancing the performance of assays and accelerating turn-around time of test results," explains Richard Creager, VP of Beckman Coulter's Immunoassay Business Center. Beckman expects to take a charge of about $36 million for in-process R&D when the deal closes at the end of 2007
You may also be interested in...
Beckman Coulter, Lumigen make it official
Beckman Coulter gains access to Lumigen's technology for immunochemical and other high-sensitivity testing via its $185 mil. acquisition, expected to close by Nov. 1. Having partnered with Lumigen for more than 10 years, Beckman Coulter has already drawn from the company's well; Lumigen's chemiluminescent chemistry is the cornerstone of Beckman Coulter's Access family of immunoassay systems, the Oct. 2 release says...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.